Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
For a hedged play on Myriad Genetics (MYGN), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Aug 17, 2018 $39 covered call for a net debit in the $36.39 area. That is also the break-even stock …
Myriad Genetics Inc. (MYGN) reported first quarter EPS of $0.31 Tuesday morning, which surpassed analysts' expectations of $0.27. Myriad Genetics climbed until mid-morning Tuesday and advanced further late in the afternoon. …
NASDAQ: MYGN investors should contact the Shareholders Foundation ... and other legal related news to the …
Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the …
Myriad Genetics, Inc. MYGN was a big mover last session, as its shares rose over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for …
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc. (MYGN), if they purchased the …